PHS
VRDN icon

PFM Health Sciences’s Viridian Therapeutics VRDN Stock Holding History

PFM Health Sciences’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-360,830
Closed -$5.54M – 76
2023
Q3 		$5.54M Buy
360,830
+67,690
+23% +$1.29M 0.26% 62
2023
Q2 		$6.97M Buy
+293,140
New +$7.52M 0.27% 66

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

PFM Health Sciences's VRDN Position: Q4 2023 in Review

PFM Health Sciences sold out of Viridian Therapeutics (VRDN) in Q4 2023, closing a stake of 360,830 shares — an estimated $5.54M sold.

PFM Health Sciences first reported a position in VRDN in Q2 2023 and held it in 2 quarters. The position peaked at $6.97M in Q2 2023. 132 funds tracked by Wall St. Rank hold VRDN as of Q4 2023.

  • PFM Health Sciences reported no remaining Viridian Therapeutics position as of Q4 2023 after selling out during the quarter.
  • PFM Health Sciences sold 360,830 Viridian Therapeutics shares in Q4 2023, an estimated $5.54M.
  • PFM Health Sciences first reported a position in Viridian Therapeutics in Q2 2023 and held it in 2 quarters.
  • PFM Health Sciences's Viridian Therapeutics position peaked at $6.97M in Q2 2023.
  • 132 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2023.

Based on PFM Health Sciences's 13F filing for Q4 2023, filed 14 Feb 2024.